A modified cathelicidin peptide from snake venom (Cath-A) effectively killed drug-resistant bacteria and destroyed their biofilms at low concentrations, and was successfully produced using recombinant E. coli at 17.6 mg/L.
MIC 8-16 μg/mL against A. baumanniiThe snake-derived Cath-A peptide killed drug-resistant Acinetobacter isolates from hospital equipment at low concentrations and also destroyed their protective biofilms.
What the researchers found
Cath-A inhibited growth of A. baumannii clinical isolates from medical instruments at MIC values of 8-16 μg/mL. Against P. aeruginosa, MICs ranged from 16 to ≥256 μg/mL. The peptide significantly removed established biofilms of both species. Cath-A showed minimal hemolytic and cytotoxic activity against eukaryotic cells. Recombinant production in E. coli BL21 using pET-32a(+) vector with thioredoxin fusion yielded 17.6 mg/L of partially purified peptide with confirmed antimicrobial activity after enterokinase cleavage.
Why it matters
Hospital-acquired infections from drug-resistant bacteria like A. baumannii kill thousands of patients annually, and biofilm formation on medical devices makes these infections nearly impossible to treat with conventional antibiotics. Antimicrobial peptides represent a fundamentally different mechanism of killing bacteria that is harder for pathogens to develop resistance against, making Cath-A and similar peptides promising alternatives.
How the study worked
Researchers designed Cath-A, a 34-amino-acid derivative of cathelicidin-BF from snake venom. Antimicrobial activity was tested against A. baumannii and P. aeruginosa isolates from hospital medical instruments using standard MIC determination. Biofilm disruption was assessed on established biofilms. For production, the Cath-A gene was cloned into pET-32a(+) and expressed as a thioredoxin fusion protein in E. coli BL21. Purification used Ni2+ affinity chromatography followed by enterokinase cleavage to release the mature peptide.
What this study cannot tell us
All testing was in vitro — no animal infection models were used. The P. aeruginosa MICs were highly variable (16 to ≥256 μg/mL), suggesting inconsistent activity against this pathogen. The peptide was only partially purified, and the 17.6 mg/L yield may need significant optimization for commercial production. Stability in biological fluids, pharmacokinetics, and in vivo toxicity were not assessed. The specific biofilm disruption mechanism was not elucidated.
How to read the evidence
This is an in vitro laboratory study demonstrating both antimicrobial activity and recombinant production. While the methods are standard and the results clear, the lack of in vivo data and the partial purification of the recombinant product limit the translational significance.
When this study was published
Published in 2018, this study contributes to the ongoing research into antimicrobial peptides as alternatives to conventional antibiotics. The antibiotic resistance crisis has only intensified since publication.
The bigger picture
Antimicrobial resistance is a global health crisis, and the pipeline of new conventional antibiotics has slowed dramatically. Antimicrobial peptides from animal venoms represent an untapped reservoir of novel anti-infective agents. This study advances the field by both identifying an effective peptide and demonstrating a scalable production method — addressing the two key barriers (efficacy and manufacturing) that have limited AMP clinical development.
Questions still open
- Can Cath-A maintain its antibiofilm activity in vivo, where biological fluids and immune factors are present?
- Could the production yield be improved enough to make Cath-A commercially viable as a medical device coating or topical antimicrobial?
- Why is Cath-A much less effective against P. aeruginosa compared to A. baumannii, and can the peptide be further modified to improve this?
Common questions
How can snake venom peptides fight antibiotic-resistant bacteria?
Can antimicrobial peptides break through bacterial biofilms?
Read the original research
A Recombinant Snake Cathelicidin Derivative Peptide: Antibiofilm Properties and Expression in Escherichia coli.
Biomolecules, 8(4)
Citation
Tajbakhsh, Mercedeh; Akhavan, Maziar Mohammad; Fallah, Fatemeh; Karimi, Abdollah. (2018). A Recombinant Snake Cathelicidin Derivative Peptide: Antibiofilm Properties and Expression in Escherichia coli.. Biomolecules, 8(4). https://doi.org/10.3390/biom8040118